Patents by Inventor Katja GROSSE-SENDER

Katja GROSSE-SENDER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID FORMS OF [(1S)-1-[(2S,4R,5R)-5-(5-AMINO-2-OXO-THIAZOLO[4,5-D]PYRIMIDIN-3-YL)-4-HYDROXY-TETRAHYDROFURAN-2-YL]PROPYL] ACETATE
    Publication number: 20220119415
    Abstract: The present invention relates to novel solid forms of compound (I), [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 21, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Katja GROSSE-SENDER, Urs SCHWITTER, Frank STOWASSER, Xuemei WANG, Jing XIONG
  • SOLID FORMS OF [(1S)-1-[(2S,4R,5R)-5-(5-AMINO-2-OXO-THIAZOLO[4,5-D]PYRIMIDIN-3-YL)-4-HYDROXY-TETRAHYDROFURAN-2-YL]PROPYL] ACETATE
    Publication number: 20220119414
    Abstract: The present invention relates to novel solid forms of compound (I), [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 21, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Katja GROSSE-SENDER, Urs SCHWITTER, Frank STOWASSER, Xuemei WANG, Jing XIONG
  • Solid forms of [(1 S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-D]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-Yl]proptl] acetate
    Patent number: 11230559
    Abstract: The present invention relates to novel solid forms of compound (I) [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: January 25, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Katja Grosse-Sender, Urs Schwitter, Frank Stowasser, Xuemei Wang, Jing Xiong
  • SOLID FORMS OF [(1 S)-1 -[(2S,4R,5R)-5-(5-AMINO-2-OXO-THIAZOLO[4,5-D]PYRIMIDIN-3-YL)-4-HYDROXY-TETRAHYDROFURAN-2-YL]PROPYL] ACETATE
    Publication number: 20200024288
    Abstract: The present invention relates to novel solid forms of compound (I) [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate and pharmaceutical compositions comprising the solid forms thereof disclosed herein, which may be used as a TLR7 agonist, or for the treatment or prophylaxis of a viral disease in a patient relating to HBV infection or a disease caused by HBV infection.
    Type: Application
    Filed: January 4, 2018
    Publication date: January 23, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Katja GROSSE-SENDER, Urs SCHWITTER, Frank STOWASSER, Xuemei WANG, Jing XIONG
  • Polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene) sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid
    Patent number: 10011584
    Abstract: The invention relates to a polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene)sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid which is stable at room temperature and is therefore useful for preparing stable pharmaceutical formulations.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: July 3, 2018
    Assignee: ATOPIX THERAPEUTICS LIMITED
    Inventors: Katja Grosse-Sender, Rolf Hilfiker
  • Polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene) sulfonyl] pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid
    Patent number: 9951042
    Abstract: The invention relates to a polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene)sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid which has higher solubility than other forms and is therefore useful for preparing stable pharmaceutical formulations.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: April 24, 2018
    Assignee: ATOPIX THERAPEUTICS LIMITED
    Inventors: Rolf Hilfiker, Katja Grosse-Sender
  • POLYMORPHIC FORM OF [5-FLUORO-3-(METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID
    Publication number: 20170121306
    Abstract: The invention relates to a polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene)sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid which has higher solublity than other forms and is therefore useful for preparing stable pharmacetical formulations.
    Type: Application
    Filed: May 1, 2015
    Publication date: May 4, 2017
    Inventors: Rolf HILFIKER, Katja GROSSE-SENDER
  • POLYMORPHIC FORM OF [5-FLUORO-3-(METHYL)-2-METHYLINDOL-1-YL]-ACETIC ACID
    Publication number: 20170057944
    Abstract: The invention relates to a polymorphic form of [5-fluoro-3-({2-[(4-fluorobenzene)sulfonyl]pyridin-3-yl}methyl)-2-methylindol-1-yl]-acetic acid which is stable at room temperature and is therefore useful for preparing stable pharmaceutical formulations.
    Type: Application
    Filed: May 1, 2015
    Publication date: March 2, 2017
    Inventors: Katja GROSSE-SENDER, Rolf HILFIKER